La vendita allo scoperto per British American Tobacco dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di British American Tobacco. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

British American Tobacco (NYSE:BTI) Azioni, Report sulle vendite allo scoperto

British American Tobacco

British American Tobacco  Industries, p.l.c.

AMEX

The second-largest tobacco company by volume, British American Tobacco sold 555 billion cigarettes in 2023. Its leading brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans in cigarettes. Its ownership of the Camel, Natural American Spirit, and Newport brands are limited to the us. In next-generation products, the company has the Vuse brand in vaping, Glo in heated tobacco, and Velo in modern oral tobacco. The company also owns a 25.5% stake in ITC limited, the largest Indian cigarette company.

British American Tobacco Industries, p.l.c. Common Stock ADR

British American Tobacco PLC

Boatim Inc

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Farmer Bros Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARM#NASDAQ">FARM</a>)</h3>
<ul>
<li>On Sept. 12, Farmer Bros reported better-than-expected fourth-quarter financial results. &#8220;This past year was a transformative one for Farmer Brothers,&#8221; said President and Chief Executive Officer John Moore. &#8220;The decision to sell our direct ship business and focus on our more profitable DSD business helped significantly improve our gross margins and drive adjusted EBITDA profitability and overall operational efficiency.&#8221; The company's stock fell around 30% over the past month and has a <a href="https://www.benzinga.com/quote/FARM">52-week low of $1.85</a>.</li>
<li>RSI Value: 27.27</li>
<li>FARM Price Action: Shares of Farmer Bros fell 2.1% to close at $1.89 on Thursday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100424&amp;t=be2bearmibe3na1">latest FARM news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100424&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="817" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04065613/image-16.png" alt="" class="wp-image-580375" style="width:634px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04065613/image-16.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04065613/image-16-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04065613/image-16-768x696.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<h3 class="wp-block-heading">British American Tobacco PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTI#NYSE">BTI</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On July 25, British American Tobacco posted H1 adjusted EPS of 169.3p down from 181.6p in the year-ago period. The company's stock fell around 6% over the past five days. It <a href="https://www.benzinga.com/quote/MMYT">has a 52-week low</a> of $28.25.</li>
<li>RSI Value: 24.49</li>
<li>BTI Price Action: Shares of British American Tobacco fell 2.4% to close at $35.11 on Thursday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100424&amp;t=be2bearmibe3na1">trend in BTI stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100424&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="905" height="823" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04065652/image-17.png" alt="" class="wp-image-580377" style="width:637px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04065652/image-17.png 905w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04065652/image-17-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04065652/image-17-768x698.png 768w" sizes="(max-width: 905px) 100vw, 905px" /></a></figure>
<h3 class="wp-block-heading">Conagra Brands Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>)</h3>
<ul>
<li>On Oct. 2, ConAgra Brands reported worse-than-expected first-quarter financial results. Conagra Brands reaffirmed its fiscal 2025 guidance, projecting organic net sales to be between a decline of 1.5% and flat compared to fiscal year 2024, and expects adjusted earnings per share (EPS) to be between $2.60 and $2.65, compared to an estimated $2.61. The company's shares fell around 10% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/CAG">low of $25.16</a>.</li>
<li>RSI Value: 25.52</li>
<li>CAG Price Action: Shares of Conagra Brands fell 2.4% to close at $29.35 on Thursday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100424&amp;t=be2bearmibe3na1">breakout in CAG shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100424&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="852" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04065730/image-18.png" alt="" class="wp-image-580379" style="width:611px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04065730/image-18.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04065730/image-18-300x282.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04065730/image-18-768x721.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41173410/top-2-tech-and-telecom-stocks-that-are-ticking-portfolio-bombs">Top 2 Tech And Telecom Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

FARM

Top 3 Risk Off Stocks That May Explode This Month

Whales with a lot of money to spend have taken a noticeably bearish stance on British American Tobacco.
Looking at options history for British American Tobacco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTI#NYSE">BTI</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 20% of the investors opened trades with bullish expectations and 70% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $760,250 and 6, calls, for a total amount of $378,890.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $28.0 to $42.0 for British American Tobacco during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in British American Tobacco's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to British American Tobacco's substantial trades, within a strike price spectrum from $28.0 to $42.0 over the preceding 30 days.
<h3>British American Tobacco Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727370982_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BTI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$7.2</td>
<td>$6.8</td>
<td>$7.2</td>
<td>$40.00</td>
<td>$262.8K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">365</td>
</tr>
<tr>
<td>BTI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$5.2</td>
<td>$4.9</td>
<td>$5.2</td>
<td>$37.00</td>
<td>$189.8K</td>
<td style="text-align: right;">23</td>
<td style="text-align: right;">730</td>
</tr>
<tr>
<td>BTI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$5.1</td>
<td>$4.8</td>
<td>$5.1</td>
<td>$37.00</td>
<td>$186.1K</td>
<td style="text-align: right;">23</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>BTI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$9.5</td>
<td>$8.1</td>
<td>$8.1</td>
<td>$42.00</td>
<td>$121.5K</td>
<td style="text-align: right;">134</td>
<td style="text-align: right;">150</td>
</tr>
<tr>
<td>BTI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$3.4</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$37.00</td>
<td>$109.5K</td>
<td style="text-align: right;">15</td>
<td style="text-align: right;">730</td>
</tr>
</tbody>
</table>

<h3>About British American Tobacco</h3>
The second-largest tobacco company by volume, British American Tobacco sold 555 billion cigarettes in 2023. Its leading brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans in cigarettes. Its ownership of the Camel, Natural American Spirit, and Newport brands are limited to the us. In next-generation products, the company has the Vuse brand in vaping, Glo in heated tobacco, and Velo in modern oral tobacco. The company also owns a 25.5% stake in ITC limited, the largest Indian cigarette company.
After a thorough review of the options trading surrounding British American Tobacco, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>British American Tobacco's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 3,193,902, the BTI's price is down by -0.03%, now at $37.95. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 12 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for British American Tobacco, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Looking At British American Tobacco's Recent Unusual Options Activity

Financial giants have made a conspicuous bullish move on British American Tobacco. Our analysis of options history for British American Tobacco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTI#NYSE">BTI</a>) revealed 14 unusual trades.
Delving into the details, we found 42% of traders were bullish, while 28% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $109,361, and 11 were calls, valued at $501,442.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $32.0 to $40.0 for British American Tobacco over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for British American Tobacco options trades today is 2179.8 with a total volume of 5,347.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for British American Tobacco's big money trades within a strike price range of $32.0 to $40.0 over the last 30 days.
<h3>British American Tobacco Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726605064_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BTI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$0.9</td>
<td>$0.85</td>
<td>$0.9</td>
<td>$39.00</td>
<td>$90.0K</td>
<td>738</td>
<td>1.1K</td>
</tr>
<tr>
<td>BTI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$4.2</td>
<td>$4.1</td>
<td>$4.2</td>
<td>$34.00</td>
<td>$78.9K</td>
<td>4.1K</td>
<td>630</td>
</tr>
<tr>
<td>BTI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.0</td>
<td>$1.7</td>
<td>$1.8</td>
<td>$40.00</td>
<td>$54.1K</td>
<td>2.6K</td>
<td>301</td>
</tr>
<tr>
<td>BTI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$0.7</td>
<td>$0.65</td>
<td>$0.66</td>
<td>$37.00</td>
<td>$53.1K</td>
<td>596</td>
<td>939</td>
</tr>
<tr>
<td>BTI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.2</td>
<td>$3.7</td>
<td>$4.01</td>
<td>$35.00</td>
<td>$40.1K</td>
<td>3.5K</td>
<td>293</td>
</tr>
</tbody>
</table>

<h3>About British American Tobacco</h3>
The second-largest tobacco company by volume, British American Tobacco sold 555 billion cigarettes in 2023. Its leading brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans in cigarettes. Its ownership of the Camel, Natural American Spirit, and Newport brands are limited to the us. In next-generation products, the company has the Vuse brand in vaping, Glo in heated tobacco, and Velo in modern oral tobacco. The company also owns a 25.5% stake in ITC limited, the largest Indian cigarette company.
Following our analysis of the options activities associated with British American Tobacco, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of British American Tobacco</h3>
<ul>
<li>With a volume of 5,754,079, the price of BTI is down -3.43% at $38.01. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 14 days.</li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest British American Tobacco options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

British American Tobacco Options Trading: A Deep Dive into Market Sentiment

Cannabis producer Organigram Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/OGI#TSX">OGI</a>) has closed the second of three tranches of the previously announced CA$124,559,674 ($92.3 million) follow-on strategic equity investment by BT DE Investments Inc., a wholly owned subsidiary of British American Tobacco plc, (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTI#NYSE">BTI</a>) on Tuesday.
Under the second tranche closing, the investor acquired Organigram's 4,429,740 common shares and 8,463,435 Class A preferred shares at CA$3.2203 per share, for gross proceeds of $30.8 million.
The company said on Tuesday that the remaining 12,893,175 shares subscribed for are due to be issued at the per-share price in the final tranche on or around February 28, 2025.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/03083439/ccc-oct-24-banner__1_.gif" alt="" class="wp-image-526880" /></figure>
"With two tranches of the Jupiter pool now funded, combined with our strong balance sheet and targeted investment strategy, Organigram is well on its way to executing on its ambitious growth plan focusing on international, technological and product expansion," Paolo De Luca, chief strategy officer of Organigram. "Our inaugural Jupiter investment in Open Book Extracts marked our second investment in the U.S. market, and our first international investment in Sanity Group represents a significant first step in our ambitions to grow our footprint in the fast-growing German market."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40337376/organigram-reports-25-yoy-increase-in-q3-net-revenue-significant-improvement-in-adjusted-ebitda">Organigram Reports 25% YoY Increase In Q3 Net Revenue, Significant Improvement In Adjusted EBITDA</a> 
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">The Deal Details</h3>
Organigram first announced a CA$124.6 million follow-on strategic equity investment <a href="https://www.benzinga.com/markets/cannabis/23/11/35617810/69b-tobacco-giant-supports-cannabis-with-91m-investment-in-toronto-weed-producer">from BAT's subsidiary in November 2023</a>. In January 2024, Organigram shareholders voted to approve the investment from BAT, and the company completed the first of three tranches of the investment for proceeds of CA$41.5 million.
The investment allows Organigram to &#8220;fully leverage our world-class facilities, market leadership in several categories, and cutting-edge research and development capabilities to increase Organigram's reach both within the Canadian market and beyond," Beena Goldenberg, the company's CEO said earlier this year.
As previously announced, Organigram is using most of the investment to fund a strategic investment pool named Jupiter. This pool is designed to accelerate Organigram's international expansion and targets investments both overseas and in the U.S. Following the closing of the first tranche in January, Organigram has already made two important investments from the Jupiter Pool.
The first investment of $2 million was made in North Carolina-based hemp producer Open Book Extracts, while the second investment of €14 million ($15 million), was made in Sanity Group GmbH, a <a href="https://www.benzinga.com/markets/cannabis/24/06/39484091/organigram-supports-cannabis-in-germany-with-15m-initial-investment-in-this-berlin-marijuana-co">market leader in the fast-growing German medical market.</a>
BAT initially invested approximately CA$221 million into Organigram in March of 2021, which had served to propel product innovations resulting from CoE at the company's Moncton facility.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/39720383/a-2-billion-opportunity-in-cannabis-how-a-tobacco-giant-is-helping-organigram-seize-the-german-m">A $2 Billion Opportunity In Cannabis: How A Tobacco Giant Is Helping Organigram Seize The German Market</a></li>
</ul>
<h3 class="wp-block-heading">OGI Price Action</h3>
Organigram's shares traded 0.54% lower at $1.84 per share during the pre-market session on Tuesday morning.

Cannabis

Financing

TSX:OGI

Tobacco Giant Invests $30.8M In Cannabis Company: BAT Private Placement Second Of Three Tranches

FDA Issues Final Rule Increasing Minimum Age For Tobacco Sales Restrictions; From Sept. 30, Retailers Must Verify Age With Photo ID For Anyone Under 30 And Vending Machine Sales Will Be Limited To 21+ Facilities

As of July 25, 2024, three stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Unilever plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UL#NYSE">UL</a>)</h3>
<ul>
<li>On July 25, Unilever reported quarterly adjusted earnings of $1.74 per share. This is a 16.27% increase over earnings of $1.50 per share from the same period last year. The company reported $33.48 billion in sales this quarter. The company's stock gained around 19% over the past six months and has a <a href="https://www.benzinga.com/quote/UL">52-week high of $58.62</a>.</li>
<li>RSI Value: 71.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>UL Price Action: Shares of Unilever gained 0.04% to close at $56.54 on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">British American Tobacco PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTI#NYSE">BTI</a>)</h3>
<ul>
<li>On July 25, British American Tobacco posted H1 adjusted EPS of 169.3p down from 181.6p year over year. The company's stock gained around 4% over the past month and <a href="https://www.benzinga.com/quote/BTI">has a 52-week high</a> of $34.15.</li>
<li>RSI Value: 77.99</li>
<li>BTI Price Action: Shares of British American Tobacco fell slightly to close at $33.38 on Wednesday.</li>
</ul>
Altria Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>)
<ul>
<li>Altria Group will report its second-quarter and first-half business results on July 31. The company's stock gained around 6% over the past month and has a <a href="https://www.benzinga.com/quote/MO">52-week high</a> of $49.92.</li>
<li>RSI Value: 76.01</li>
<li>MO Price Action: Shares of Altria closed at $49.42 on Wednesday.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39954998/over-1m-bet-on-united-security-bancshares-check-out-these-3-stocks-insiders-are-buying">Over $1M Bet On United Security Bancshares? Check Out These 3 Stocks Insiders Are Buying</a></li>
</ul>

Short Ideas

Top 3 Defensive Stocks That Are Ticking Portfolio Bombs

WIIM

British American Tobacco shares are trading higher following H1 earnings.

Earnings

British American Tobacco H1 Adj. EPS 169.3p Down From 181.6p YoY, Revenue £12.34B Down From £13.44B YoY

After an extensive scientific review, the Food and Drug Administration (FDA) <a href="https://www.fda.gov/tobacco-products/ctp-newsroom/fda-authorizes-marketing-vuse-alto-tobacco-flavored-e-cigarette-pods-and-accompanying-power-unit" target="_blank" rel="noreferrer noopener">issued </a>marketing granted orders to R.J. Reynolds Vapor Company, a subsidiary of British American Tobacco P.L.C. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTI#NYSE">BTI</a>), for the Vuse Alto Power Unit and six Vuse Alto tobacco-flavored pods, which are sealed, pre-filled, and non-refillable.
While the FDA is authorizing the marketing of these tobacco products in the U.S., it does not mean these tobacco products are safe nor are they &#8220;FDA approved.&#8221;
Additionally, this action is not an authorization or indication of appropriateness to market these products as modified risk tobacco products.
FDA evaluates premarket tobacco product application (PMTAs) based on a public health standard that considers the risks and benefits of the product to the population as a whole.
After reviewing the company&#8217;s applications, FDA determined there was sufficient evidence to demonstrate that permitting marketing of the products would be appropriate for the protection of public health.
The applicant showed that these tobacco-flavored products could benefit adults who smoke cigarettes sufficiently to outweigh the risks, including to youth.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/39796877/philip-morris-expands-us-operations-with-600m-colorado-plant" rel="noreferrer noopener">Philip Morris Expands US Operations With $600M Colorado Plant</a>
According to the 2023 National Youth Tobacco Survey, Vuse was among the most commonly reported brands used by middle and high school students currently using e-cigarettes.
Only 6.4% of these students reported using tobacco-flavored products. To further mitigate youth use, FDA has placed stringent marketing restrictions on the new products and will closely monitor their marketing practices.
However, these products have continued to be sold while the ruling is challenged in court, <a target="_blank" href="https://www.wsj.com/business/retail/u-s-authorizes-tobacco-flavored-vuse-e-cigarettes-f6f6f3b5?mod=retail_news_article_pos1" rel="noreferrer noopener">reported </a>The Wall Street Journal.
The decision by the FDA comes after a previous ruling prohibiting Reynolds American to sell the brand&#8217;s menthol versions.
The FDA&#8217;s decisions on Vuse are part of a comprehensive federal review of the vaping industry, requiring all U.S. e-cigarette manufacturers to provide evidence that their products are less harmful than cigarettes and offer a public-health benefit by helping smokers switch to a safer option.
The report further noted that Vuse Alto products accounted for approximately 40% of U.S. e-cigarette sales in stores tracked by Nielsen IQ for the year ending June 15, with menthol flavors making up $1.5 billion of the total sales.
Tobacco flavors represented $479 million in sales. Reynolds American also markets Camel and Newport cigarettes and recently introduced a nicotine-free vaping brand called Sensa.
Price Action: BTI shares are trading higher by 0.15% at $33.09 in premarket at last check Friday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo via Midjourney
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/06/39377842/whats-happening-with-tobacco-major-philip-morris-shares-on-tuesday" target="_blank" rel="noreferrer noopener">Swedish Match North America subpoenaed over D.C. flavored sales</a></li>
</ul>

Equities

Media

General

FDA Approves Tobacco-Flavored Vuse Alto E-Cigarettes: Details

Whales with a lot of money to spend have taken a noticeably bearish stance on British American Tobacco.
Looking at options history for British American Tobacco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTI#NYSE">BTI</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 11% of the investors opened trades with bullish expectations and 88% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $252,279 and 2, calls, for a total amount of $109,000.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $30.0 to $35.0 for British American Tobacco over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for British American Tobacco options trades today is 930.0 with a total volume of 1,591.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for British American Tobacco's big money trades within a strike price range of $30.0 to $35.0 over the last 30 days.
<h3>British American Tobacco Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721318515_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BTI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$4.3</td>
<td>$4.2</td>
<td>$4.2</td>
<td>$30.00</td>
<td>$84.0K</td>
<td>2.7K</td>
<td style="text-align: right;">202</td>
</tr>
<tr>
<td>BTI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$0.6</td>
<td>$0.55</td>
<td>$0.6</td>
<td>$33.00</td>
<td>$80.7K</td>
<td>420</td>
<td style="text-align: right;">35</td>
</tr>
<tr>
<td>BTI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$7.2</td>
<td>$3.0</td>
<td>$5.9</td>
<td>$35.00</td>
<td>$29.5K</td>
<td>1</td>
<td style="text-align: right;">30</td>
</tr>
<tr>
<td>BTI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$5.7</td>
<td>$5.1</td>
<td>$5.7</td>
<td>$35.00</td>
<td>$28.5K</td>
<td>1</td>
<td style="text-align: right;">250</td>
</tr>
<tr>
<td>BTI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$5.7</td>
<td>$5.1</td>
<td>$5.7</td>
<td>$35.00</td>
<td>$28.5K</td>
<td>1</td>
<td style="text-align: right;">200</td>
</tr>
</tbody>
</table>

<h3>About British American Tobacco</h3>
The second largest tobacco company by volume, British American Tobacco sold 555 billion cigarettes in 2023. Its leading brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans in cigarettes. Its ownership of the Camel, Natural American Spirit, and Newport brands are limited to the us. In next-generation products, the company has the Vuse brand in vaping, Glo in hated tobacco, and Velo in modern oral tobacco. The company also owns a 25.5% stake in ITC limited, the largest Indian cigarette company.
Following our analysis of the options activities associated with British American Tobacco, we pivot to a closer look at the company's own performance.
<h3>Where Is British American Tobacco Standing Right Now?</h3>
<ul>
<li>With a volume of 3,288,650, the price of BTI is up 1.74% at $33.27. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 12 days.</li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for British American Tobacco, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

R.J. Reynolds Gets FDA Marketing Approval For 7 Vuse E-Cigarettes

On July 10, Zuanic &amp; Associates hosted a panel discussion focusing on the European cannabis market, featuring Benna Goldenberg, CEO of Organigram Holdings (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ogi#NASDAQ">OGI</a>), and Finn Age Hansel, CEO of Sanity Group.
Senior analyst <a href="https://www.benzinga.com/topic/pablo-zuanic">Pablo Zuanic</a> led the discussion, which centered on the companies&#39; strategies for expanding in Germany and the broader European market.
<h2>Organigram&#39;s Strategic Move In Germany</h2>
<a href="https://www.benzinga.com/markets/cannabis/24/05/38811412/organigram-reports-262-higher-quarterly-net-loss-yoy-makes-progress-in-international-markets">Organigram</a> has been actively expanding its presence in the international markets, with a particular focus on Germany. And, according to CEO Benna Goldenberg, the company&#39;s <a href="https://www.benzinga.com/markets/cannabis/23/05/32531812/organigram-to-enter-german-cannabis-market-via-sanity-group">partnership </a>with Sanity Group is a key element in this strategy. The collaboration is bolstered by British American Tobacco (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bti#NYSE">BTI</a>), a strategic investor in both companies.
<h3>Investment Details And Strategic Goals</h3>
Organigram&#39;s initial investment in Sanity Group amounted to &euro;14 million ($15.22 million), comprising &euro;11.5 million through an unsecured convertible note and &euro;2.5 million for purchasing equity interest from founders and other shareholders.
This investment includes an option to advance an additional &euro;3 million based on achieving specific milestones. The partnership also grants Organigram a board seat in Sanity Group, enhancing its influence and oversight.
<h3>Sanity Group&#39;s Market Presence And Growth</h3>
Goldenberg sees multiple strategic benefits in this partnership, arguing that Sanity Group&#39;s established market presence in Germany and its strong distribution network make it an ideal partner. The company&#39;s position as the number two player in the German flower market, combined with its successful pilot test in Switzerland, showcases its capability and<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39470142/canadian-vs-u-s-cannabis-companies-who-is-winning-the-market-race-to-weed-profits"> market reach</a>.
Sanity Group&#39;s CEO, Finn Age Hansel, further elaborated on the company&#39;s operations and growth in Germany. The company currently holds a market share of around 15% in the German flower market, selling approximately 300 kg of products monthly. This consistent sales volume speaks to its solid footing in the market.
In terms of financial performance, Sanity Group has seen its revenues grow to approximately &euro;2 million per month. Hansel is optimistic about the future, projecting a tenfold increase over the next two years. He attributes part of this growth to the significant uptick in medical cannabis prescriptions since Germany reclassified cannabis on April 1, 2024. According to Hansel, this reclassification has driven the market upwards by 50%, signaling a robust demand and promising future for the medical cannabis industry in Germany.
Read Also:&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39609582/europe-is-turning-cash-flow-positive-well-see-what-happens-in-the-u-s-largest-canna">Europe Is Turning Cash Flow Positive, &#39;We&#39;ll See What Happens In The U.S.,&#39; Says Curaleaf&#39;s Boris Jordan</a>
<h3>Market Potential And Projections</h3>
Goldenberg and Hansel both highlighted the substantial <a href="https://www.benzinga.com/markets/cannabis/24/06/39484091/organigram-supports-cannabis-in-germany-with-15m-initial-investment-in-this-berlin-marijuana-co">potential of the German market</a>. Goldenberg noted that before recreational legalization, Canada&#39;s medical cannabis market boasted about CAD 1 billion in sales. With Germany&#39;s population being twice that of Canada, they estimate the German medical cannabis market could reach approximately &euro;2 billion before transitioning to a recreational market.
From a market share perspective, Hansel emphasized, &ldquo;The flower market is the most relevant market in Germany right now.&rdquo; Considering that Sanity Group currently sells around 300 kg of its product into the German market each month, Hansel said, &ldquo;We believe our market share is around 50% right now. We are around &euro;2 million in monthly revenues,&quot; with the domestic market accounting for about 95% of their sales.
<h3>Infrastructure And Capabilities</h3>
Sanity Group operates an EU-GMP facility in Frankfurt, allowing it to process and distribute cannabis products efficiently. The company collaborates with cultivators like Organigram to ensure a consistent supply of <a href="https://www.benzinga.com/markets/cannabis/24/05/39040158/organigram-and-this-canadian-cannabis-brand-expand-in-europe-and-beyond">high-quality products</a>.
Hansel also discussed Sanity Group&#39;s expansion into telemedicine, a rapidly growing sector in Germany. The company believes that telemedicine will play a crucial role in the market&#39;s growth, potentially increasing the patient base from the current 0.15% to 1.5% of the population.
As the conversation progressed, Hansel expressed skepticism about cultivating cannabis in Germany due to its high costs. He stated, &quot;The costs of cultivation in Germany will always be a competitive disadvantage <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39146622/cannabis-slowdown-in-canada-analyst-spotlights-what-still-sells-and-where-the-money">compared to Canada </a>and other markets.&quot;
Meanwhile, Goldenberg highlighted the company&#39;s capacity to meet increasing demand.&nbsp;
<h3>Markets: Social Clubs And Medical Grade Cannabis&nbsp;</h3>
The discussion also touched on the potential impact of decriminalization and social clubs in Germany.
Hansel downplayed the risk to the medical cannabis market, stating, &quot;I believe in coexistence. Medical cannabis will continue to be sourced from professional cultivators like Organigram.&quot;
Read Next:<a href="https://www.benzinga.com/markets/cannabis/23/10/35162283/investing-in-germanys-cannabis-hemp-industry-ceos-insights-on-consumer-needs-and-revenue-streams">&nbsp;Investing In Germany&#39;s Cannabis: Hemp Industry CEO&#39;s Insights On Consumer Needs And Revenue Streams</a>
These issues will be a hot topic&nbsp;at the upcoming Benzinga Cannabis Capital Conference in Chicago this Oct. 8-9. Join us to get more insight into what the wave of weed legalization means for the future of investing in the&nbsp;industry. Hear directly from top executives, investors, advocates, and policymakers.&nbsp;<a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" rel="noreferrer noopener" target="_blank">Get your tickets now</a>&nbsp;before prices go up by following&nbsp;<a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" rel="noreferrer noopener" target="_blank">this link</a>.
Photo: AI-Generated Image.&nbsp;

Market Summary

Penny Stocks

Guidance

Emerging Markets

Contracts

Global

Exclusives

A $2 Billion Opportunity In Cannabis: How A Tobacco Giant Is Helping Organigram Seize The German Market

<a href="https://www.statnews.com/2024/06/28/vape-makers-fda-supreme-court-chevron-doctrine/">https://www.statnews.com/2024/06/28/vape-makers-fda-supreme-court-chevron-doctrine/</a>
&nbsp;
WASHINGTON &mdash; Vape manufacturers are taking a victory lap over a Supreme Court decision that could dramatically weaken the Food and Drug Administration&#39;s power to regulate tobacco and nicotine products as regulators see fit.
The court on Friday overturned a judicial rule, known as the Chevron doctrine, which instructed courts to defer to regulators on certain legal issues. Vape manufacturers see the decision as a powerful weapon in their fight against the FDA&#39;s efforts to ban the majority of vapes lining store shelves.
The FDA has argued that its decision to ban more than 1 million vapes is in line with a 2009 law that instructed the agency to approve new tobacco and nicotine products only when they are &quot;appropriate for the protection of public health,&quot; and vape companies have repeatedly tried, and largely failed, to convince judges that the FDA&#39;s approach has been unlawful. Now, buoyed by the Supreme Court&#39;s decision, the two vaping trade organizations in Washington see potential for a major breakthrough.

&nbsp;

Legal

XXII

"Vape Makers See Supreme Court Ruling As A Weapon In Fighting FDA; The Court On Friday Overturned A Judicial Rule, Known As The Chevron Doctrine, Which Instructed Courts To Defer To Regulators On Certain Legal Issues" - STAT News

The U.S. Supreme Court has overturned a <a href="https://www.benzinga.com/government/24/06/39530590/supreme-court-decision-curtails-secs-use-of-internal-tribunals-for-fraud-cases">40-year-old decision</a> that gave the executive branch the power to rule on laws passed by Congress that were unclear.
The decision, known as the Chevron doctrine, stems from a unanimous Supreme Court case involving the energy company in an argument over the Clean Air Act that upheld an action by the Environmental Protection Agency under then-President Ronald Reagan.
Since then, the Chevron decision has required judges to defer to agencies' reasonable interpretations of congressional statutes. Friday&#8217;s 6-3 ruling to overturn the doctrine allows judges to decide on laws that are considered ambiguous.
The 1984 ruling has long been in the crosshairs of conservatives and business groups who argue that it gives too much power to the executive branch, the Associated Press<a href="https://apnews.com/article/supreme-court-chevron-regulations-environment-4ae73d5a79cabadff4da8f7e16669929"> reported</a>.
Read Also: <a href="https://www.benzinga.com/general/politics/24/06/39552967/supreme-court-backs-jan-6-rioter-could-this-affect-trumps-case">Supreme Court Backs Jan. 6 Rioter: Could This Affect Trump&#8217;s Case?</a>
The Biden administration has defended the law, warning that overturning it would be destabilizing and could bring a "convulsive shock" to the nation's legal system.
But groups representing the gun industry and other businesses such as tobacco, agriculture, timber and homebuilding have urged the Supreme Court to overturn the decades-old ruling.
The Supreme Court took a close look at the Chevron ruling in January when presiding over a case brought by herring fishermen who objected to being forced to pay for federal inspections of their catch,&nbsp;USA Today <a href="https://www.usatoday.com/story/news/politics/2024/01/17/supreme-court-herring-fishermen-case/72254165007/">reported</a>.
Price Action: Makers of guns, tobacco and timber saw their stocks having mixed reactions to the Supreme Court decision by midday Friday. Smith &amp; Wesson Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWBI#NASDAQ">SWBI</a>) slipped 2.2% to $14.45, while Olin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) edged up 0.24% to $47.74.
Phillip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) shed 0.33% to $101.23 and British American Tobacco p.l.c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTI#NYSE">BTI</a>) jumped 0.24% to $30.97. International Paper Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IP#NYSE">IP</a>) slid 0.08% to $43.22 by midday on Friday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/24/06/39538825/massachusetts-attorney-general-says-sacklers-will-be-held-responsible-after-supreme-court-vacates-pu">Massachusetts Attorney General Says Sacklers &#8216;Will Be Held Responsible&#8217; After Supreme Court Vacates Purdue Bankruptcy Plan</a></li>
</ul>
Photo: Shutterstock

Government

Regulations

Politics

SWBI

Supreme Court Overturns Chevron Ruling: Biden Administration Warns Of 'Convulsive Shock'

British American Tobacco PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTI#NYSE">BTI</a>) stock is turning heads on Wall Street with a classic bullish signal approaching: <a href="https://www.benzinga.com/topic/golden-cross">the Golden Cross</a>. 
This technical pattern, where the 50-day simple moving average (SMA) rockets past the 200-day SMA, often heralds a strong upward trend. But that&#8217;s just the beginning of the company&#8217;s bullish bonanza.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="628" height="452" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/26090057/Screenshot-2024-06-26-at-5.45.03-PM.png" alt="" class="wp-image-406460" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/26090057/Screenshot-2024-06-26-at-5.45.03-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/26090057/Screenshot-2024-06-26-at-5.45.03-PM-300x216.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></figure>
<h3 class="wp-block-heading">Technicals Indicate Strong Bullish Momentum</h3>
The Golden Cross is just one of several technical metrics supporting a bullish stance on British American Tobacco. The stock is currently trading at $32.13, well above its 5, 20, and 50-day exponential moving averages (EMAs). This positioning indicates a strong bullish trend, reinforced by slight buying pressure in the market.
<ul>
<li>50-day SMA vs. 200-day SMA: With the 50-day SMA now at $30.45, crossing above the 200-day SMA at $30.48, British American Tobacco is clearly on a bullish path.</li>
<li>Current Share Price: BTI's share price of $32.13 surpasses several key moving averages, including the 8-day SMA ($31.37), 20-day SMA ($31.06), and 50-day SMA ($30.45). Each of these signals reinforcing short-to-medium term bullishness.</li>
<li>MACD Indicator: The Moving Average Convergence Divergence (MACD) indicator stands at 0.33, further suggesting a bullish outlook.</li>
<li>RSI and Bollinger Bands: While the Relative Strength Index (RSI) at 66.74 indicates the stock is nearing overbought territory, the Bollinger Bands suggest bullishness, with the stock trading in the upper, bullish band.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/news/earnings/24/05/38897083/3-tobacco-stocks-worth-watching-amid-industry-challenges">3 Tobacco Stocks Worth Watching Amid Industry Challenges</a>
<h3 class="wp-block-heading">Fueling the Fire: BTI's Bold Buyback</h3>
Adding fuel to BTI&#8217;s bullish fire, the company recently completed a hefty share buyback. 
On June 26, British American Tobacco scooped up 200,000 ordinary shares from UBS AG, part of a buyback program announced on March 18. The shares bought back will be canceled, shrinking the total number of shares in circulation to 2,221,832,242.
This move is a clear sign of confidence from British American Tobacco's management, directly benefiting shareholders and tightening the supply of available shares.
With the Golden Cross initiating a bullish trail and a slew of technical indicators backing up the trend, British American Tobacco stock is grabbing its share of spotlight in the market. 
The recent share buyback only adds to the bullish sentiment, signaling management&#8217;s faith in the company&#8217;s future prospects. 
For investors, BTI is a stock worth watching closely as it rides this wave of bullish momentum.
Read Next: <a href="https://www.benzinga.com//node/39343635">Tim Seymour On Running A Cannabis Fund: &#8216;We Focus On Companies Poised For Growth&#8217;</a>
Image: Courtesy of BTI

Technicals

British American Tobacco Stock Ignites Bullish Flames With Golden Cross

<a href="https://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-four-menthol-flavored-e-cigarette-products-after-extensive-scientific" title="https://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-four-menthol-flavored-e-cigarette-products-after-extensive-scientific">https://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-four-menthol-flavored-e-cigarette-products-after-extensive-scientific</a>

FDA Authorizes Marketing of Four Menthol-Flavored E-Cigarette Products After Extensive Scientific Review

Tim Seymour, portfolio manager of the $CNBS Amplify Seymour Cannabis ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cnbs#NYSE">CNBS</a>), is renowned for&nbsp;recognizing the potential of the cannabis sector early on. In an exclusive interview with Benzinga Cannabis, he discussed the critical role of strategic partnerships in expanding market reach, the importance of operational efficiencies in improving gross margins&nbsp;and the potential of the U.S. hemp cannabinoid market as a burgeoning and legally complex segment poised for substantial growth.
These insights are vital for investors looking to understand the dynamics that drive <a href="https://www.benzinga.com/markets/cannabis/24/04/38279554/cannabis-valuations-more-mathematical-more-balance-sheet-driven-than-before-insights-from-indust">profitability </a>and growth in the cannabis industry.
&ldquo;Cannabis sector growth continues to exceed expectations, particularly as regulations begin to soften worldwide. This shift is creating significant investment opportunities,&rdquo; Seymour told Benzinga. He underscored the dynamic nature of the market, fueled by regulatory changes that often catalyze growth and investor interest.
<h3>Investment Strategy And Portfolio Management</h3>
In managing the $CNBS ETF, Seymour employs a selective strategy that prioritizes companies with robust governance structures and strong market potential. &ldquo;In a nascent industry like cannabis, governance and strategic foresight are paramount.
We focus on companies that are not only well-managed but also poised for growth.
&quot;We specifically look at leaders like Curaleaf (OTC: <a class="ticker" href="https://www.benzinga.com/stock/curlf#OTC">CURLF</a>), which is renowned for its<a href="https://www.benzinga.com/markets/cannabis/24/05/38555314/exclusive-tim-seymour-stresses-germanys-role-in-shaping-cannabis-investment"> expansive operational footprint</a> and strategic partnerships that position it uniquely in both U.S. and<a href="https://www.benzinga.com/markets/cannabis/24/06/39256203/curaleaf-international-is-beating-illicit-cannabis-prices-in-uk-and-germany-whats-next-for-eu-ex"> international markets</a>. Green Thumb Industries (OTC: <a class="ticker" href="https://www.benzinga.com/stock/gtbif#OTC">GTBIF</a>) stands out due to its robust wholesale strategies and high-margin product offerings, making it a <a href="https://www.benzinga.com/markets/cannabis/23/11/35590282/green-thumb-zuanic-associates-explains-why-this-cannabis-company-stands-out">strong player</a> in the U.S. cannabis market,&rdquo;<a href="https://www.benzinga.com/markets/equities/23/12/36369921/exclusive-find-value-in-large-multinationals-and-catch-the-dividend-yield-says-tim-seymour"> Seymour </a>noted.
&ldquo;Meanwhile, Trulieve (OTC: <a class="ticker" href="https://www.benzinga.com/stock/tcnnf#OTC">TCNNF</a>) leverages its strong presence in<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38470560/landing-in-floridas-cannabis-market-legal-adult-use-marijuana-could-yield-874m-in-2"> Florida</a> to optimize production efficiencies and market penetration, setting industry benchmarks for <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38772876/cannabis-reports-highlight-339m-and-297-6m-revenue-insights-in-curaleaf-and-truliev">profitability</a>. These companies exemplify the type of growth and governance we seek in our investment choices. These are the types of companies that attract institutional investments first,&rdquo; Seymour said.&nbsp;
<h3>The Importance Of Gross Margins</h3>
Seymour explained how operational efficiencies contribute to improving gross margins across the cannabis sector.
&quot;Companies like <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39214567/rumors-of-green-thumb-and-boston-beer-merger-what-investors-need-to-know-analyst-br">Green Thumb</a> have honed their focus on high-margin product lines and strategic wholesale operations. For instance, Green Thumb&rsquo;s <a href="https://www.benzinga.com/markets/cannabis/24/05/38716589/green-thumb-industries-revenue-increases-11-in-q1-2024-were-off-to-a-great-start-says-pres">first-quarter sales</a> demonstrated a robust gross margin,&quot; he noted.
&quot;By optimizing production processes and reducing overhead costs, companies can substantially increase their gross margins. This has been evident in cases where operational refinements have led to reduced production costs, directly enhancing profitability,&quot; he added. This strategy mirrors an industry-wide move towards price stabilization and operational optimization to boost EBITDA margins, essential for sustaining profitability amid market volatility.
<h3>Strategic Partnerships And Market Movements</h3>
Seymour highlighted the impact of strategic partnerships in the space, such as British Tobacco&rsquo;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bti#NYSE">BTI</a>) investment in the Canadian cannabis company&nbsp;Organigram (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ogi#NASDAQ">OGI</a>).
&ldquo;The involvement of British Tobacco it&rsquo;s a strategic catalyst that opens doors to international markets and more sophisticated product developments.&rdquo;&nbsp;Seymour also discussed the promising developments in the U.S. hemp cannabinoid market, highlighting Organigram&rsquo;s strategic investments in this area.
<h3>Emerging Opportunities In Hemp And THC Products</h3>
&ldquo;The U.S. <a href="https://www.benzinga.com/general/biotech/23/06/33036049/interstate-hemp-tapping-into-potential-of-nationwide-shipping-and-strategic-partnerships-for-mark">hemp cannabinoid market</a> is legally complex yet burgeoning, with potential sales estimated around $25 billion. Organigram&rsquo;s move into this market through strategic investments positions them well to capitalize on this growth,&rdquo; he said.
&quot;The move into the hemp market is not just about diversifying products but aligning with the <a href="https://www.benzinga.com/general/biotech/23/03/31227249/from-controversial-to-profitable-why-nestl-procter-gamble-pepsico-and-other-cpg-brands-should-emb">CPG sector&#39;s standards</a> and practices, which are well-established and consumer-oriented.&quot;&nbsp;
This strategic alignment with <a href="https://www.benzinga.com/markets/cannabis/23/06/33061096/turnaround-potential-amazon-nestl-and-p-g-who-will-revive-dying-cannabis-brands">CPG practices</a> helps&nbsp;build a sustainable business model that can thrive in a competitive market.
This approach, according to Seymour, positions companies to better <a href="https://www.benzinga.com/markets/cannabis/23/05/32494325/cpg-wine-strategies-for-cannabis-marketing-from-terroir-to-strains-what-can-we-learn">manage risks</a>, enhancing investor confidence.
Discussing the future, Seymour sees a dynamic market where <a href="https://www.benzinga.com/news/earnings/24/06/39303117/these-states-could-go-fully-legal-soon-this-cannabis-company-could-win-big-a-top-stock-pick-trading">state-level changes </a>drive industry growth more significantly than federal reforms, with states like <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/39076254/top-ohio-cannabis-companies-analyst-look-at-stocks-with-potential-market-cap-gains">Ohio</a>, Florida&nbsp;and <a href="https://www.benzinga.com/topic/pennsylvania-cannabis">Pennsylvania </a>playing pivotal roles.
Learn more about leading cannabis companies and stocks, at&nbsp;the&nbsp;<a href="https://cannabismarketspotlight.com/" rel="noopener noreferrer" target="_blank">Benzinga Cannabis Market Spotlight</a>&nbsp;in New Jersey on June 17th! Grow your business, raise money, and capitalize on the booming NJ recreational market. Don&rsquo;t miss this must-attend event in New Brunswick. Secure your tickets now. Very few spots are left.&nbsp;<a href="https://www.eventbrite.com/e/benzinga-market-spotlight-new-jersey-cannabis-registration-871406729987?discount=JAVIER20" rel="noopener noreferrer" target="_blank">Use the code &quot;JAVIER20&quot; for 20% off!</a>
<img alt="c.events_600x250_0.png" src="https://www.benzinga.com/files/u503488/c.events_600x250_0.png" style="height:264px; width:633px" />
Photo: AI-Generated Image.&nbsp;

Analyst Color

Emerging Market ETFs

Small Cap

Management

Analyst Ratings

Interview

ETFs

CNBS

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

GTBIF

TCNNF

Tim Seymour On Running A Cannabis Fund: 'We Focus On Companies Poised For Growth'

U.S. FDA Says Justice Department And FDA Announce Federal Multi-Agency Task Force To Curb Distribution And Sale Of Illegal E-Cigarettes

<a href="https://www.wsj.com/business/fda-rescinds-juul-ban-opening-door-for-federal-clearance-acc14955?page=1" title="https://www.wsj.com/business/fda-rescinds-juul-ban-opening-door-for-federal-clearance-acc14955?page=1">https://www.wsj.com/business/fda-rescinds-juul-ban-opening-door-for-federal-clearance-acc14955?page=1</a>
The Food and Drug Administration rescinded its 2022 ban on Juul Labs&#39;s e-cigarettes. The agency hasn&#39;t yet reached a final determination on whether they can stay on the U.S. market, but the move opened the possibility for federal clearance.
The FDA in 2022 ordered Juul to halt its sales, then stayed the order pending the vaping company&#39;s appeal. The agency said Thursday that it was placing Juul&#39;s products back under scientific review, essentially moving them back to their regulatory status before the ban.

'FDA Rescinds Juul Ban, Opening Door For Federal Clearance; E-Cigarette Maker's Products Have Stayed On Market Pending Appeal Of 2022 Ban' - WSJ

This Action, Prompted By New Case Law And Additional Information From The Applicant, Returns JUUL&#39;s Applications To Pending Status Under FDA Review. The Rescission Is Neither An Authorization Nor A Denial, And The FDA Is Limited In Disclosing Details Of Pending Applications.

FDA Rescinds June 2022 Marketing Denial Orders For JUUL Labs

Is It Time To Start Selling Altria, British American And Philip Morris? 4 Things You Need To Know

11 Great Dividend Aristocrat Bargain Buys For The Market At Record Highs

The Retiree's Taxable Dividend August 2024 Portfolio Review - Energy Sector Starts To Look Interesting Again

Janus Henderson Global Equity Income Fund Q2 2024 Commentary

British American Tobacco Yields ~8%, But Total Shareholder Yield Could Be 10%+

14 Incredible High-Yield Dividend Aristocrat Bargain Buys For October

British American Tobacco: Shares Getting Close To The Tipping Point (Rating Downgrade)

British American Tobacco: Quality At A Huge Discount

British American Tobacco set for seven straight sessions of losses

British American Tobacco: Still A Solid Income Play

AAUKF

BNPQF

BNPQY

BPAQF

BTAFF

CINF

CTBI

DTGHF

DTRUY

EPDU

FELE

HBCYF

HNHAF

HNHPF

HSBC

MDTTF

NGLOY

PDRDF

PRNDY

QCOM

SRCE

SSNLF

THFF

TOELF

TOELY

TROW

TSMWF

UNLYF

Press Releases

BTI IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages British American Tobacco p.l.c Investors to Secure Counsel Before Important March 25 Deadline in Securities Class Action Commenced by the Firm – BTI

MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that British American Tobacco p.l.c. Investors with Substantial Losses Have Opportunity to Lead Case

The Gross Law Firm Notifies British American Tobacco p.l.c. Investors of a Class Action Lawsuit and Upcoming Deadline - BTI

BTI Investors Have Opportunity to Lead British American Tobacco p.l.c. Securities Fraud Lawsuit

BRITISH AMERICAN TOBACCO 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against British American Tobacco p.l.c - BTI

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against British American Tobacco p.l.c. - BTI

DEADLINE ALERT for BTI, XPOF, LUXH, and AMLX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

BTI DEADLINE TODAY: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages British American Tobacco p.l.c Investors with Losses in Excess of $100K to Secure Counsel Before Important March 25 Deadline in Securities Class Action Commenced by the Firm – BTI

Charlotte's Web Reports 2024 First Quarter Financial Results

AMLX

CWBHF

LUXH

TSX:CWEB

XPOF

Ispire Technology

Altria Group

Philip Morris International Inc Common Stock

Philip Morris Intl

RLX Technology Inc. American Depositary Shares, each representing the right to receive one (1) Class A ordinary share

Comments

British American Tobacco

Vendite allo scoperto

British American Tobacco (NYSE:BTI) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO